Rui Cheng

Xinxiang Ruicheng Technology Co., Ltd. (hereinafter referred to as "Ruicheng Technology"), established in 2000 and headquartered in the eastern section of Qinglong Road, Xinxiang Economic Development Zone, is a high-tech enterprise integrating R&D, production, and sales. The company focuses on the development and industrialization of nucleoside and antiviral APIs and vitamin intermediates. Its core products include nucleoside pharmaceutical intermediates such as adenine, cytosine, tetraacetylribose, and hypoxanthine, which are widely used in the production of antiviral APIs.